FLGT

FLGT is a post-COVID recovery story wrapped around a rare asset-value case. Revenue collapsed from $993M (FY2021) to a $283M trough (FY2024) as pandemic testing evaporated, but FY2025 revenue grew +13.8% to $323M and gross profit rose +22.1% to $131M — the core molecular-testing and pathology business is genuinely re-accelerating, and management is buying growth (Bako Diagnostics + StrataDx pathology labs for ~$55.5M cash, closing 1H2026, all from cash on hand). The balance sheet is the anchor: $1.21B assets against just $107M liabilities, $1.11B of equity, and a liabilities/equity of 0.10x. At a $651M market cap the stock trades near 0.6x book — the market is paying roughly 60 cents for a dollar of largely liquid net assets ($550M current assets), which is a real floor under the price.

The offset is that this is still an unprofitable, cash-consuming business. FY2025 net loss widened to -$60.5M and operating income was -$91.1M (-28.2% margin), dragged by $53.9M of R&D as management funds the therapeutic-development segment — the FID-007 and FID-022 cancer candidates the MD&A explicitly warns will require 'significant research and development expenses' in later-stage trials. The headline -$102M operating cash flow (a -583% swing) is heavily distorted by a discretionary one-time item: the $99.5M cash purchase of $106.3M in Investment Tax Credits. Strip that and the underlying cash burn is far more moderate, but the direction — an asset-heavy testing company diverting capital into speculative oncology R&D — is exactly what keeps the stock at a discount to book.